Asia MDS Registry: Real-world Insights from Asia
Official title: Asia Myelodysplastic Syndrome (MDS) Registry
Run by Bristol-Myers Squibb · NCT07355478 · Data updated 2026-11-12
This registry collects real-world data on adults with myelodysplastic syndromes in Asia to see how they are diagnosed, treated, and what outcomes they experience.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Locations | 3 sites (Singapore and 2 other locations) |
| Status | Recruiting |
| Started | August 11, 2026 |
| Main results expected | October 31, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT07355478 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) diagnosed with MDS by WHO criteria (2008, 2016, or 2022) with retrospectively identified cases from 2019-2022 or prospectively identified cases from 2025-2026 at participating sites in Asia.
✕Probably not a fit
Patients not receiving similar treatments as captured in routine care or those with diagnoses outside the specified WHO criteria or time windows may not derive direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry compiles retrospective and prospective data on adults diagnosed with myelodysplastic syndromes across Asia, focusing on demographics, clinical features, treatment patterns, and real-world outcomes. Data are drawn from multiple sites, including Singapore, Seoul, and Taipei, with inclusion of cases diagnosed between 2019-2022 (retrospective) and planned 2025-2026 (prospective) using WHO criteria. The study aims to provide contemporary, region-wide insights into how MDS is managed in real-world clinical practice. Interventions consist of prescribed MDS treatments as they occur in routine care, without randomized assignments. There are no exclusion criteria beyond eligibility for participation, and the sponsor is Bristol-Myers Squibb in collaboration with participating centers.
Why it matters
Potential benefit: If successful, the registry could clarify real-world treatment patterns and outcomes to inform clinicians and researchers about regional practice and unmet needs.
How similar studies have gone: Real-world MDS registries have yielded useful clinical and demographic insights in other regions, supporting the value of this Asia-focused registry.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants: * Aged at least 18 years at initial diagnosis of MDS * Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and * Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate Inclusion criteria for the prospective enrolment of MDS participants: * Aged at least 18 years at initial diagnosis of MDS; and * Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and * Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate Exclusion Criteria: • None
Where it's running
-
Singapore General Hospital
Singapore, Singapore Recruiting -
Local Institution - 002
Seoul, Seoul Teugbyeolsi, South Korea Not yet recruiting -
Local Institution - 0001
Taipei, Taiwan Not yet recruiting
Study contacts
- Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor
This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.
-
Personalized dosing of azacytidine for patients with blood cancers
This study is testing if adjusting the dose of azacytidine based on patients' genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes get better results with fewer side effects.
-
Evaluating the response to a biosimilar treatment for anemia in MDS patients
This study is testing how well a new version of an anemia treatment works for people with Myelodysplastic Syndromes who have either responded to the original treatment before or are starting it for the first time.
-
Combining ICP-248 with Azacitidine for treating Acute Myelogenous Leukemia
This study is testing whether a new drug called ICP-248, when combined with azacitidine, can safely help people with Acute Myelogenous Leukemia feel better and improve their treatment outcomes.
-
Treatment for Myelodysplastic Syndromes with IDH1 Mutation
This study is testing whether a new drug called ivosidenib can help people with myelodysplastic syndromes and an IDH1 mutation feel better compared to the standard treatment with azacitidine.
-
Using Darzalex Faspro to lower antibody levels before stem cell transplant
This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.